VERIX
AtlasCompare
Metabolic & Body Comp
Cognitive & Nootropic
Clinical
Research chemical

Tesofensine

Also known as Tesofensine · NS2330 · triple monoamine reuptake inhibitor

Available sizes & price

Catalog only

500mcg x 100

Tesofensine Capsules · Not in current stock

$20 / vial

Add

Prices per vial · Research use only · Not medical advice.

Oral triple monoamine reuptake inhibitor (dopamine, norepinephrine, serotonin) studied for substantial weight loss; not a peptide but listed in oral research-capsule catalogs.

How to picture it

A triple monoamine reuptake inhibitor (DA/NE/5-HT) researched for appetite suppression and energy expenditure — more classic CNS appetite pharmacology than a gut-hormone mimetic. Picture a central multi-channel appetite lever with notable clinical-development history in obesity research. Not a peptide; included because it appears in oral research catalogs alongside peptide products.

Research focus & benefits

  • Central appetite and weight-loss research
  • Triple monoamine pathway studies
  • Obesity clinical-development history

Benefits describe research interest and pathway rationale — not guaranteed outcomes or medical advice. Research use only.

Overview

Tesofensine was developed for obesity and neurodegenerative indications. Phase 2 obesity data showed large placebo-adjusted weight loss. It is a small molecule, not a peptide — included because VERIX oral capsule SKUs list it alongside peptide capsules.

Mechanism

Inhibits reuptake of DA/NE/5-HT, reducing appetite and increasing energy expenditure indirectly via central monoamine tone.

Research uses

  • Phase 2 obesity weight-loss trials
  • Parkinson/Alzheimer exploratory history

Research dosing notes

Clinical trials used ~0.25–1 mg daily ranges with careful titration. Research capsules require extreme dose caution due to potency and CV effects.

Half-life / kinetics

~220 hours (very long; active metabolites)

Common research routes

Oral

Reported considerations

  • Heart rate and blood pressure increases
  • Insomnia
  • Dry mouth
  • Mood changes
  • Abuse potential theoretical

Contraindications / cautions

  • Cardiovascular disease
  • Uncontrolled hypertension
  • MAOI use
  • Pregnancy

Common research stacks

  • Often monotherapy in trials

Legal / access note

Not currently an approved obesity drug in the US. Research chemical / capsule listings only.